Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

PTC Therapeutics reported a phase 2 win for its Novartis-partne | PTC Therapeutics reported a phase 2 win for its ...

Just before the May 5 trial date set for Novartis and Incyte to finally hash out their Jakafi royalty dispute in court, the ...

Swiss pharmaceutical giant Novartis (SIX:NOVN) has reaffirmed its commitment to producing life-saving treatments for malaria ...

The Novartis oncology strategy focuses on people living with cancer and those who care for them, from loved ones to clinical care teams, including their providers. For the past 30+ years, the aim has ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

Headquartered in Basel, Novartis (NVS) is a Medical stock that has seen a price change of 17.45% so far this year. Currently paying a dividend of $2.6 per share, the company has a dividend yield of ...

These approvals will change the paradigm for treating cancer patients,” Narasimhan says. The medicine now approved for use ...

LONDON (Reuters) -Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of ...